Swedish Orphan Biovitrum AB is to acquire the US specialty pharmaceutical company Dova Pharmaceuticals Inc in a bid to broaden its haematology and immunology portfolios. The transaction is valued at up to $915 million and consists of a cash offer plus a contingency payment for shareholders if Dova’s lead product is approved for a new indication by the US Food and Drug Administration.
This product, Doptelet (avatrombopag), has been approved in the US and Europe for the treatment of thrombocytopenia in adult patients with chronic liver disease. Thrombocytopenia is a condition in which a person has a low blood platelet count. In June, Doptelet received a new indication in the US for the treatment of adults with chronic immune thrombocytopenia, a rare autoimmune bleeding disorder. It is also in a Phase 3 trial for chemotherapy-induced thrombocytopenia, which if approved, would trigger the release of the contingency payments. There are currently no approved treatments for chemotherapy-induced thrombocytopenia.
Sobi announced the acquisition on 30 September, one day after it disclosed plans to expand a haemophilia collaboration with Sanofi SA giving it opt-in rights to an investigational drug for haemophilia A. The drug, BIVV001 was initially developed by Bioverativ, a company acquired by Sanofi in 2018 for $11.6 billion. Sobi said the expanded agreement with Sanofi will strengthen its position in haemophilia, while the acquisition of Dova will broaden its portfolio into haematology and strengthen its commercial position in the US.
Copyright 2019 Evernow Publishing Ltd